(Q38016532)

27 August 2017

title

New developments in castrate-resistant prostate cancer (English)

1 reference

27 August 2017

1 reference

N Shore

1

1 reference

27 August 2017

M Mason

series ordinal

2

1 reference

27 August 2017

Th M de Reijke

series ordinal

3

1 reference

27 August 2017

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

109 Suppl 6

1 reference

27 August 2017

page(s)

22-32

1 reference

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Evidence-based standards for cancer pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Targeting continued androgen receptor signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Therapeutic cancer vaccines in combination with conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

New therapies for castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

The role of Src in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Genomic strategy for targeting therapy in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

A review of the history, properties, and use of the immunomodulatory compound lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

The epothilones: new therapeutic agents for castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11217.X

10.1111/J.1464-410X.2012.11217.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference